Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share & Trends Analysis Report By Service Type, By Synthesis Type, By Therapeutic Category, By Animal Type, By Region, And Segment Forecasts, 2023 - 2030

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share & Trends Analysis Report By Service Type, By Synthesis Type, By Therapeutic Category, By Animal Type, By Region, And Segment Forecasts, 2023 - 2030

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Growth & Trends

The global veterinary active pharmaceutical ingredients manufacturing market size is expected to reach USD 10.64 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 6.9% from 2023 to 2030. The key factors driving the industry growth include the growing animal population, rising pet ownership & humanization, high pet expenditure, an increasing number of veterinarians & veterinary visits, and a high prevalence of zoonotic diseases. In addition, the rising demand for pet insurance, strategic initiatives undertaken by key participants, and government initiatives are likely to boost industry growth.Various government policies are affecting the veterinary active pharmaceutical ingredients (API) manufacturing.

For instance, in India, despite a strong base, domestic veterinary pharmaceutical companies have gradually stopped manufacturing veterinary APIs due to low-profit margins. They started importing APIs from other countries, a majority of which are imported from China, which was a cheaper alternative and increased their profit margin on drugs. The Technology Information Forecasting and Assessment Council-an organization under the Department of Science & Technology, India-recommended a few guidelines to address the need for regulating APIs to make India self-reliant and revive its economy post-pandemic. This is important to reduce India’s dependency on China for pharmaceutical goods, including APIs, especially after the tensions between soldiers at the India–China border.

Various guidelines are being issued by government organizations to encourage veterinary services globally, which is anticipated to aid veterinary API manufacturing market growth in the coming years. An increase in the number of government initiatives that help promote animal health is also expected to fuel the overall market growth during the forecast period. The launch of One Health Initiative for enhancing animal healthcare standards has improved growth prospects for the industry. This joint project unified clinical care, disease surveillance, and education & research areas for better control of diseases. The growing need for efficient animal treatment and increasing awareness about pathogenesis & epidemiology have encouraged organizations, such as Companion Animal Adoption Resources and the Federation of European Companion Animal Veterinary Association, to take appropriate measures.

Government and private organizations are constantly updating their guidelines to promote animal health and prevent obesity & other disorders. This is expected to fuel industry growth over the forecast period.The increasing number of oral formulations for various veterinary drugs is boosting the demand for veterinary APIs. These majorly include nonsteroidal anti-inflammatory drugs. Manufacturers are investing in electrochemical synthesis, which helps in accelerating the manufacturing process for APIs. In addition, the introduction of biologically synthesized APIs is a technological innovation that fuels industry growth. Going forward, veterinary biopharmaceuticals produced by rDNA technology will be gaining more significance, as they would be a better choice for managing diseases, such as arthritis, cancer, & diabetes, and autoimmune disorders.

Furthermore, the introduction of High-Potency APIs (HPAPIs), which act on the target cells in a much lower dose as compared to the general APIs, is also expected to offer lucrative growth opportunities in the vet API Manufacturing market. The HPAPIs are creating significant changes in pharmaceutical innovation to deliver new therapeutic medicines.Some of the macroeconomic factors, such as COVID-19, have widely impacted veterinary consumer demand, as human medicines, including antivirals, were in high requirement during the pandemic. According to SeQuent Scientific Ltd., 2021, rising geopolitical tensions amid the Ukraine-Russia conflicts are also expected to create uncertainty in the supply chain, financial stress, & climate-related changes, as well as increase inflation in the near term.

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report Highlights

  • Some API manufacturing companies have been gaining traction since the COVID-19 pandemic
  • For instance, the share of companies, such as Lasa Supergenerics-a company involved in veterinary and human APIs-increased to 108% by February 2020 compared to February 2019 owing to the exponential rise in the demand for human APIs by drug manufacturers
  • The contract outsourcing segment accounted for the highest revenue share in 2022 owing to its associated benefits. Earlier, veterinary pharma drug manufacturers would opt for an in-house model and prepare their APIs
  • The chemical-based API segment is expected to drive industry growth over the forecast period owing to its high usage among veterinary pharmaceutical companies
  • The anti-infectives segment dominated the industry in 2022. Growing challenges among livestock owners to uphold veterinary health standards to meet the demand for healthy dairy products, fresh meat, and dietary nutrition are driving the need for anti-infective drug production
  • North America is expected to dominate the industry over the forecast perioddue to the high prevalence of zoonotic diseases across the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources & Third-Party Perspectives
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information/Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 Market Definitions
1.8 List Of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot, 2022
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Analysis
3.1.2 Ancillary Market Analysis
3.2 Penetration And Growth Prospect Mapping, By Synthesis Type, 2022
3.3 Veterinary Api Manufacturing Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing Prevalence Of Zoonotic Diseases
3.3.1.2 Increasing Animal Population And Pet Ownership
3.3.1.3 Growing Pet Expenditure
3.3.1.4 Rising Number Of Veterinarians And Veterinary Visits
3.3.1.5 Growing Demand For Pet Insurance
3.3.1.6 Strategic Initiatives Undertaken By Market Players
3.3.1.7 Growing Government Initiatives
3.3.2 Market Restraint Analysis
3.3.2.1 Stringent Government Regulations
3.3.2.2 Lack Of Awareness And High Cost Of Animal Care
3.3.3 Market Challenges Analysis
3.3.3.1 Illegal Veterinary Medicines
3.3.3.2 Challenges In Large Molecule Api Synthesis
3.4 Veterinary Active Pharmaceutical Ingredients (Api) Manufacturing Market Analysis Tools: Porters
3.4.1 Bargaining Power Of Suppliers: Low
3.4.2 Bargaining Power Of Buyers: Moderate
3.4.3 Threat Of Substitutes: Moderate
3.4.4 Threat Of New Entrants: Moderate
3.4.5 Competitive Rivalry: High
3.5 Veterinary Active Pharmaceutical Ingredients (Api) Manufacturing Market Analysis Tools: Pest Analysis
3.5.1 Political & Legal Landscape
3.5.2 Economic Landscape
3.5.3 Social Landscape
3.5.4 Technology Landscape
3.6 Regulatory Landscape
3.6.1 North America
3.6.2 Europe
3.6.3 Asia-Pacific
3.6.4 Latin America
3.6.5 MEA
3.7 Pricing Analysis
3.8 Forecast Analysis
3.8.1 Technology & Trends In Api Manufacturing
Chapter 4 Service Type Estimates & Trend Analysis, 2018 - 2030 (USD Million)
4.1 Service Type Movement Analysis, 2018 - 2030 (USD Million)
4.2 Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market Share Analysis, 2022 & 2030
4.3 In-House
4.3.1 In-House Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4 Contract Outsourcing
4.4.1 Contract Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2 Contract Development
4.4.2.1 Contract Development Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2.2 Preclinical Development
4.4.2.2.1 Preclinical Development Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2.3 Others
4.4.2.3.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3 Contract Manufacturing
4.4.3.1 Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3.2 Api/Bulk Drugs
4.4.3.2.1 Api/Bulk Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3.3 Finished Dose Formulations
4.4.3.3.1 Finished Dose Formulations Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Synthesis Type Estimates & Trend Analysis, 2018 - 2030 (USD Million)
5.1 Synthesis Type Movement Analysis, 2018 - 2030 (USD Million)
5.2 Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market Share Analysis, 2022 & 2030
5.3 Chemical-Based Api
5.3.1 Chemical-Based Active Pharmaceutical Ingredients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4 Biological Api
5.4.1 Biological Active Pharmaceutical Ingredients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5 Hpapi
5.5.1 Hpapi Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Therapeutic Category Estimates & Trend Analysis, 2018 - 2030 (USD Million)
6.1 Therapeutic Category Movement Analysis, 2018 - 2030 (USD Million)
6.2 Veterinary Active Pharmaceutical Ingredients (Api) Manufacturing Market Share Analysis, 2022 & 2030
6.3 Antiparasitic
6.3.1 Antiparasitic Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4 Anti-Infectives
6.4.1 Anti-Infectives Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5 Nsaids
6.5.1 Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6 Others
6.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Animal Type Estimates & Trend Analysis, 2018 - 2030 (USD Million)
7.1 Animal Type Movement Analysis, 2018 - 2030 (USD Million)
7.2 Veterinary Active Pharmaceutical Ingredients (Api) Manufacturing Market Share Analysis, 2022 & 2030
7.3 Companion Animals
7.3.1 Companion Animals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Production/Food Animals
7.4.1 Production/Food Animals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Regional Estimates & Trend Analysis, 2018 - 2030 (USD Million)
8.1 Regional Market Snapshot
8.2 Regional Market Share Analysis, 2022 & 2030
8.3 North America
8.3.1 North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.3 Canada
8.3.3.1 Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4 Europe
8.4.1 Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.2 U.K.
8.4.2.1 U.K. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3 Germany
8.4.3.1 Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4 France
8.4.4.1 France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.5 Italy
8.4.5.1 Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.6 Spain
8.4.6.1 Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.2 China
8.5.2.1 China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3 Japan
8.5.3.1 Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4 India
8.5.4.1 India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6 Latam
8.6.1 Latam Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3 Mexico
8.6.3.1 Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7 MEA
8.7.1 Mea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3 Saudi Arabia
8.7.3.1 Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9 Competitive Landscape
9.1 Company Market Position Analysis
9.2 Synergy Analysis: Major Deals & Strategic Alliances
Chapter 10 Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market – Company Profiles
10.1 Alivira Animal Health Limited
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Product Benchmarking
10.1.4 Strategic Initiatives
10.2 Excel Industries Ltd.
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Product Benchmarking
10.3 Ofichem Group
10.3.1 Company Overview
10.3.2 Product Benchmarking
10.3.3 Strategic Initiatives
10.4 Chempro Pharma Private Limited
10.4.1 Company Overview
10.4.2 Product Benchmarking
10.5 Menadiona
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Product Benchmarking
10.5.4 Strategic Initiatives
10.6 SUANFARMA
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Product Benchmarking
10.6.4 STRATEGIC INITIATIVES
10.7 Vetpharma (Insud Pharma, S.L.U)
10.7.1 Company Overview
10.7.2 Product Benchmarking
10.7.3 Strategic Initiatives
10.8 Siflon Drugs
10.8.1 Company Overview
10.8.2 Product Benchmarking
10.9 Qilu Pharmaceuticals Co. Ltd.
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Product Benchmarking
10.10 FIS - Fabbrica Italiana Sintetici S.p.A.
10.10.1 Company Overview
10.10.2 Product Benchmarking
10.10.3 Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings